Outstanding presentation by Sumanta K. Pal, MD, FASCO at #ASCO25. In IMmotion010: 📍Serum KIM-1 ➡️ strongest predictor of benefit. 📍Within pts with high KIM-1 those with high T-eff had longer DFS with atezolizumab vs placebo. OncoAlert UroToday.com City of Hope

With all the amazing presentations at #ASCO25, just wanted to take a moment to share some of our data related to #biomarkers from the #IMmotion010 phase III study, a trial of adjuvant #atezolizumab vs pbo. A tremendous team helped me put this together, including Wenxin (Vincent) Xu

At #ASCO24, Laurence Albiges @gustaveroussy presented data pertaining to #KIM1, showing that high serum #KIM1 was associated with improved outcome with #atezolizumab, demonstrating for the 1st time a viable adjuvant predictive biomarker for IO in #kidneycancer. At #ASCO25, we presented

💫ASCO #ASCO25 #IMGoncCOP meeting was so genuine, collaborative, and uplifting! 💎With >200 attendees and 20 presenters, we came together to share real experiences, emotional and logistical burdens of moving from abroad, guided the next generation on tackling challenges, and

#ASCO25: City of Hope’s Sumanta K. Pal, MD, FASCO breaks down IMmotion010 — a phase 3 #clinicaltrial aiming to uncover the mechanisms behind therapy resistance in patients with localized #kidneycancer.

Dr. Dhanawat rand PhIII non-inferiority trial of adj platinum/5-FU vs platinum/paclitaxel after resected #penilecancer ➡️ due to slow accrual, study closed. Numerical improvements in PFS, OS in favor of paclitaxel arm. Applause for this trial in rare tumor #ASCO25 OncoAlert

PhI trial of pasritimag (FIH BiTE targeting kallikrein 2) in heavily pretreated #mCRPC (median 4 prior lines) ➡️ MTD not reached. Low rate of CRS (8.9%). ORR 8%, PSA50 42.4%, rPFS 7.85 mos #ASCO25 OncoAlert

Dr. Eefsen rand PhII CheckPRO trial of nivo/ipi +/- SBRT in pretreated #mCRPC (must have 2 prior lines) ➡️ ORR 16.7% vs 22.2%, no sig diff in rPFS and OS #ASCO25 OncoAlert

Fascinating deep science analyzing molecular underpinnings of sensitivity to 177Lu-PSMA-617 by Jacob Berchuk and Emory colleagues. Why wnt leads to resistance and how to target it? AR activity associated with a/ less response - counterintuitive #ASCO25

This morning Dr. Casasanta was commanding her audience presenting on "TP53 genomic alterations including targetable TP53 Y220C mutation in clinically advanced breast cancer" at #ASCO25. Former fellow and now breast attending Dr. Du is clearly impressed. Incredible job Nicole!

It was no surprise when she got into multiple med schools & she ultimately decided to join SLU Medicine. It was bittersweet - although we were excited to see her progress in her career, she was a joy to work with & her spirit was deeply missed. (4/6)

Encouraging interim results of the phase 1/2 trial of the HPK1 inhibitor NDI-101150 were presented by David Braun for patients with clear cell renal cell carcinoma (ccRCC) showing promising antitumor activity #ASCO25. Smilow Cancer Hospital OncoAlert meetings.asco.org/abstracts-pres…

Bringing #Hollywood to #Boston in this high budget trailer for the #Uromigos25 meeting this fall. Tom Powles has put his heart & soul into designing the T-shirts you see below, and #McDermott has been investing in acting classes. Enjoy my directorial debut & ❤️the post 👇 to

Excited to share the bulk of my thesis work available online today @CancerCell. We sought to dive into the tumor microenvironment of sarcomatoid renal cell carcinomas to better understand what makes RCC tumors susceptible to immunotherapy: sciencedirect.com/science/articl… 1/n

In the future we won’t rely on pathology at surgery +/- luck to select patients for adjuvant treatment across cancers. Instead, the identification of residual disease by ctDNA/other biomarkers will be used. These data are a step towards that goal IMO. natera.com/company/news/i…

Another successful Closer To Free Ride 2025 with Chief Roy Herbst PD Dr. Hurwitz APD Dr. Podoltsev Fellows Nicole Casasanta, MD Paul Stockhammer Rajal Sharma

The future of Oncology is bright!! Nicole Casasanta, MD Müschen Lab

1/ 🚨Hot off the press ✨- Our new article evaluates the efficacy and safety of ADCs + IO in advanced urothelial carcinoma (aUC) 🩺 We conducted a systematic review & meta-analysis of 645 patients across 5 trials: • EV (anti-nectin-4) • SG (anti-TROP2) • DV (anti-HER2)

🥁#ESMO25 ABSTRACT RELEASE DAY🥁 #ESMO25 is shaping up to be one of most impactful conferences in recent memory with #PracticeChangingData in Prostate, Bladder and Kidney Cancers! 💫See list of highlighted abstracts 👇

What a pleasure to work with Vitor Abreu de Góes, MD - a terrific scholar from Einstein Hospital Israelita. Impressive presentation at #ASCOQLTY25 - & so glad he connected w Paulo G Bergerot & Cristiane D Bergerot Grupo Oncoclínicas (fmr City of Hope) as well!